Zhou X, Davenport E, Ouyang J, Hoke ME, Garbinsky D, Agarwal I, Krasa HB, Oberdhan D. Pooled data analysis of the long-term treatment effects of tolvaptan in ADPKD. Kidney Int Rep. 2022 Feb 19;7(5):1037-48. doi: 10.1016/j.ekir.2022.02.009
Chirila C, Zheng Q, Davenport E, Kaschinski D, Pfarr E, Hach T, Palencia R. Treatment satisfaction in type 2 diabetes patients taking empagliflozin compared with patients taking glimepiride. Qual Life Res. 2016 May;25(5):1199-207. doi: 10.1007/s11136-015-1140-2
Ascher-Svanum H, Novick D, Haro JM, Aguado J, Cui Z. Empirically driven definitions of "good", "moderate" and "bad" levels of functioning in the treatment of schizophrenia. Qual Life Res. 2013 Oct;22(8):2085-94.
Luciano JV, Ayuso-Mateos JL, Fernandez A, Aguado J, Serrano-Blanco A, Roca M, Haro JM. Utility of the twelve-item World Health Organization Disability Assessment Schedule II (WHO-DAS II) for discriminating depression "caseness" and severity in Spanish primary care patients. Qual Life Res. 2010 May;19(1):97-101.